Real-time enrollment status for this advanced relapsed or refractory germ cell tumours clinical trial
Current Status
Recruiting
Checked: October 15, 2026 at 8:09 AM UTC
| NCT Number | NCT07306559 |
| Recruiting Status | Recruiting |
| Condition | Advanced Relapsed or Refractory Germ Cell Tumours |
| Phase | PHASE1 |
| Target Enrollment | 187 participants |
| Active Locations | 3 sites in the US |
| Sponsor | Boehringer Ingelheim |
| Last Updated on CT.gov | August 21, 2026 (Aug 21, 2026) |
As of October 15, 2026: Clinical trial NCT07306559 is currently recruiting participants. This phase1 study for advanced relapsed or refractory germ cell tumours is actively seeking new participants at 3 locations across the United States. The study is sponsored by Boehringer Ingelheim. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07306559 is actively recruiting participants as of October 15, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 3 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07306559 was last updated Aug 21, 2026 (August 21, 2026). HelloStudys verifies this status automatically.